These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Clinical efficacy and pharmacokinetics of HMG-CoA reductase inhibitors in heart transplant patients treated with cyclosporin A. Regazzi MB; Iacona I; Campana C; Gavazzi A; Viganò M; Perani G Transplant Proc; 1994 Oct; 26(5):2644-5. PubMed ID: 7940825 [No Abstract] [Full Text] [Related]
23. Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men--a randomized, placebo-controlled study. Mallon PW; Miller J; Kovacic JC; Kent-Hughes J; Norris R; Samaras K; Feneley MP; Cooper DA; Carr A AIDS; 2006 Apr; 20(7):1003-10. PubMed ID: 16603852 [TBL] [Abstract][Full Text] [Related]
24. Ezetimibe in renal transplant patients with hyperlipidemia resistant to HMG-CoA reductase inhibitors. Langone AJ; Chuang P Transplantation; 2006 Mar; 81(5):804-7. PubMed ID: 16534487 [TBL] [Abstract][Full Text] [Related]
26. Early Improvements in insulin sensitivity and inflammatory markers are induced by pravastatin in nondiabetic subjects with hypercholesterolemia. Lee WJ; Lee WL; Tang YJ; Liang KW; Chien YH; Tsou SS; Sheu WH Clin Chim Acta; 2008 Apr; 390(1-2):49-55. PubMed ID: 18201563 [TBL] [Abstract][Full Text] [Related]
27. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study. Schuster H; Barter PJ; Stender S; Cheung RC; Bonnet J; Morrell JM; Watkins C; Kallend D; Raza A; Am Heart J; 2004 Apr; 147(4):705-13. PubMed ID: 15077101 [TBL] [Abstract][Full Text] [Related]
28. Statin specific toxicity in organ transplant recipients: case report and review of the literature. Bae J; Jarcho JA; Denton MD; Magee CC J Nephrol; 2002; 15(3):317-9. PubMed ID: 12113605 [TBL] [Abstract][Full Text] [Related]
29. Effects of cyclosporin A and FK 506 on lipid metabolism and fibrinogen in kidney transplant recipients. Hohage H; Arlt M; Brückner D; Dietl KH; Zidek W; Spieker C Clin Transplant; 1997 Jun; 11(3):225-30. PubMed ID: 9193847 [TBL] [Abstract][Full Text] [Related]
30. The effect of pravastatin and atorvastatin on coenzyme Q10. Bleske BE; Willis RA; Anthony M; Casselberry N; Datwani M; Uhley VE; Secontine SG; Shea MJ Am Heart J; 2001 Aug; 142(2):E2. PubMed ID: 11479481 [TBL] [Abstract][Full Text] [Related]
31. Effect of pravastatin treatment on the evolution of extracoronary atherosclerosis in renal transplant patients. Cofan F; Gilabert R; Zambon D; Nunez I; Ros E; Cofan M; Campistol JM; Bru C; Oppenheimer F Transplant Proc; 2002 Feb; 34(1):384-8. PubMed ID: 11959338 [No Abstract] [Full Text] [Related]
33. Cyclosporin: a pharmacoeconomic evaluation of its use in renal transplantation. Frampton JE; Faulds D Pharmacoeconomics; 1993 Nov; 4(5):366-95. PubMed ID: 10146875 [TBL] [Abstract][Full Text] [Related]
34. Does pravastatin safely and effectively improve lipid profiles in children who have received a kidney transplant? Silverstein DM Nat Clin Pract Nephrol; 2006 Jun; 2(6):306-7. PubMed ID: 16932448 [No Abstract] [Full Text] [Related]
35. Effect of pravastatin on renal transplant recipients treated with cyclosporine--4-year follow-up. Yoshimura N; Ohmori Y; Tsuji T; Oka T Transplant Proc; 1994 Oct; 26(5):2632-3. PubMed ID: 7940820 [No Abstract] [Full Text] [Related]
36. Management of dyslipidemia in renal disease and transplantation. Zolezzi M Saudi J Kidney Dis Transpl; 2006 Jun; 17(2):129-36. PubMed ID: 16903617 [No Abstract] [Full Text] [Related]